Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Mar Biotechnol (NY) ; 23(1): 149-155, 2021 Feb.
Article in English | MEDLINE | ID: covidwho-1074429

ABSTRACT

An array of infections, including the novel coronavirus (SARS-CoV-2), trigger macrophage activation syndrome (MAS) and subsequently hypercytokinemia, commonly referred to as a cytokine storm (CS). It is postulated that CS is mainly responsible for critical COVID-19 cases, including acute respiratory distress syndrome (ARDS). Recognizing the therapeutic potential of Spirulina blue-green algae (Arthrospira platensis), in this in vitro stimulation study, LPS-activated macrophages and monocytes were treated with aqueous extracts of Spirulina, cultivated in either natural or controlled light conditions. We report that an extract of photosynthetically controlled Spirulina (LED Spirulina), at a concentration of 0.1 µg/mL, decreases macrophage and monocyte-induced TNF-α secretion levels by over 70% and 40%, respectively. We propose prompt in vivo studies in animal models and human subjects to determine the putative effectiveness of a natural, algae-based treatment for viral CS and ARDS, and explore the potential of a novel anti-TNF-α therapy.


Subject(s)
COVID-19/complications , COVID-19/therapy , Cell Extracts/pharmacology , Cell Extracts/therapeutic use , Cytokine Release Syndrome/etiology , Cytokine Release Syndrome/therapy , Macrophages/drug effects , Monocytes/drug effects , Cells, Cultured , Humans , In Vitro Techniques , Spirulina/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL